Addressing challenges presented for downstream purification by changes upstream

Published: 11 March 2019
Marian Bendik
Marian Bendik
Head of Gene Therapy, Process Development at Takeda Pharmaceutical Company Limited
Marian Bendik holds a Master’s degree in Biochemistry from the University of Chemistry and Technology, Prague, Czech Republic. He then worked as an immunoassay research scientist in academia and later in industry. Afterwards, he occupied different process and manufacturing expert roles with increased responsibilities in the cell-based vaccines business unit at Baxter Bioscience. In 2014, he joined gene therapy process development team to support developing of the AAV manufacturing platform in Austria. Currently, he holds accountability for gene therapy manufacturing and acts as Site Lead Orth for Gene Therapy Center Austria at Takeda.



Marian Bendik holds a Master’s degree in Biochemistry from the University of Chemistry and Technology, Prague, Czech Republic. He then worked as an immunoassay research scientist in academia and later in industry. Afterwards, he occupied different process and manufacturing expert roles with increased responsibilities in the cell-based vaccines business unit at Baxter Bioscience. In 2014, he joined gene therapy process development team to support developing of the AAV manufacturing platform in Austria. Currently, he holds accountability for gene therapy manufacturing and acts as Site Lead Orth for Gene Therapy Center Austria at Takeda.

Read now